Nutrineal Solution for Peritoneal Dialysis 4 with 1.1% amino acids
*Company:
Baxter Holding B.V.Status:
No Recent UpdateLegal Category:
Product subject to medical prescription which may not be renewed (A)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 07 August 2023
File name
Nutrineal Package Leaflet UK.Ireland.Malta.pdf
Reasons for updating
- New PIL for new product
Updated on 26 January 2023
File name
ie-spc-2019-03-nutrineal-2299016001-mah-c.pdf
Reasons for updating
- Document format updated
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 02 April 2019
File name
ie-spc-2019-03-nutrineal-2299016001-mah-c.pdf
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 8 - Marketing authorisation number(s)
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 27 December 2017
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 27 December 2017
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.8 - Undesirable effects
- Change to section 6.4 - Special precautions for storage
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 2 - change all qualitative and quantitative compositions and change Lysine chlorhydrate to Lysine Hydrochloride.
Section 4.8 - addition reporting of suspected adverse reactions statement.
Section 6.4 - change in storage instructions - Keep in outer carton in order to protect from light.
Section 4.8 - addition reporting of suspected adverse reactions statement.
Section 6.4 - change in storage instructions - Keep in outer carton in order to protect from light.
Updated on 27 December 2017
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.8 - Undesirable effects
- Change to section 6.4 - Special precautions for storage
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
Section 2 - change all qualitative and quantitative compositions and change Lysine chlorhydrate to Lysine Hydrochloride.
Section 4.8 - addition reporting of suspected adverse reactions statement.
Section 6.4 - change in storage instructions - Keep in outer carton in order to protect from light.
Section 4.8 - addition reporting of suspected adverse reactions statement.
Section 6.4 - change in storage instructions - Keep in outer carton in order to protect from light.
Updated on 01 September 2016
Reasons for updating
- New SPC for medicines.ie
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
None provided
Updated on 01 September 2016
Reasons for updating
- New SPC for medicines.ie
Free text change information supplied by the pharmaceutical company
None provided